Melina Rodriguez: First FDA-Approved VWD Prophylaxis for All Ages
Melina Rodriguez, Founder of Health Evidence Digest, Senior Medical Editor at Precision AQ, shared a post on LinkedIn:
“Von Willebrand Disease Is the Most Common Inherited Bleeding Disorder in the World. In Young Children With Severe Disease, Prophylactic Treatment Has Lacked Any FDA-Approved Option Until Now
On July 2, 2026, the FDA expanded Wilate (von Willebrand Factor/Coagulation Factor VIII Complex Human, Octapharma) approval to include routine prophylaxis in children younger than 6 years with von Willebrand disease, making it the first and only VWF concentrate approved for prophylaxis across all ages and all VWD types.
The Phase 3 WIL-33 trial (NCT04953884; n equals 12; median age 2.0 years; severe VWD) showed a mean total ABR of 4.6 (SD 6.1) during 12 months of prophylaxis; spontaneous ABR 0.9; 98.2% of all bleeds were minor; 95.6% of treated bleeds required only 1 infusion.
This was the first dedicated prospective clinical trial of VWF prophylaxis in children under 6 worldwide.
Here is what VWD is, why prophylaxis matters for young children with severe disease, and what the WIL-33 data shows across VWD types….”
Stay updated with Hemostasis Today.
-
Jul 22, 2026, 05:26Richard Dalyai: Can AI Safely Refill Medications?
-
Jul 22, 2026, 05:15Annie Bauzon: What Is Anemia? – Microcytic, Normocytic and Macrocytic Types Explained
-
Jul 22, 2026, 05:05Rob Maloney: What If Hemophilia No Longer Needed Lifelong Treatment?
-
Jul 22, 2026, 04:59Martina Wolff: Advancing Knowledge Through Global Collaboration at ISTH 2026
-
Jul 22, 2026, 04:52G. Shellye Horowitz: Hemophilia A Genetics – Hemophilia A and Pregnancy
-
Jul 21, 2026, 23:43Shadi Tabibian: The Clinical Power of Patient Stories in Rare Bleeding Disorders
-
Jul 21, 2026, 23:35Pete Stibbs: Impressed with PE Compass and Clinical Compass from Mona Ranade and Team
-
Jul 21, 2026, 23:28Toby Richards: Important Announcement about Testing for Iron Deficiency
-
Jul 21, 2026, 21:12Ammar Al Awawdeh: Bridging the Hemostatic Gap – Functional Platelet Salvage in CPB